Literature DB >> 273923

Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway.

D T Fearon.   

Abstract

Sheep erythrocytes in their native state did not activate the alternative complement pathway, as measured by lysis in dilutions of normal human serum containing [ethylenebis(oxyethylenenitrilo)] tetraacetic acid but acquired this capacity after membrane sialic acid residues had been removed (by sialidase) or modified (by NaIO(4)). Activation of the alternative pathway by sheep erythrocytes required removal or modification of at least 40% of the membrane sialic acid to reach threshold, and it increased proportionately when larger amounts of sialic acid had been affected. Studies with isolated proteins of the alternative pathway demonstrated that the altered erythrocyte membranes resembled natural activators in protecting bound C3b from inactivation by C3b inactivator and beta1H and protecting bound amplification C3 convertase (C3b,Bb) from decay-dissociation by beta1H. A 1% decrease in intact sialic acid was associated with a 1% decrease in beta1H activity in decay-dissociation of membrane bound C3b,Bb. Because removal of the C8 and C9 carbon atoms from the polyhydroxylated side chain of sialic acid by oxidation with NaIO(4) was functionally equivalent to removal of the entire sialic acid moiety, secondary effects of the latter reaction, such as diminution of the negative charge of the membrane or exposure of penultimate galactose residues, were not considered to be responsible for the altered activity of beta1H. These studies suggest that facilitation, by membrane sialic acid residues, of the interaction between bound C3b and beta1H is essential to prevent the particle from effectively activating the alternative pathway.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 273923      PMCID: PMC392464          DOI: 10.1073/pnas.75.4.1971

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  The thiobarbituric acid assay of sialic acids.

Authors:  L WARREN
Journal:  J Biol Chem       Date:  1959-08       Impact factor: 5.157

2.  INTERACTION OF AUTOLOGOUS COMPLEMENT WITH RED CELLS IN THE ABSENCE OF ANTIBODY.

Authors:  A P DALMASSO; H J MUELLER-EBERHARD
Journal:  Proc Soc Exp Biol Med       Date:  1964-12

3.  pH dependent hemolytic systems. I. Their relationship to paroxysmal nocturnal hemoglobinuria.

Authors:  S YACHNIN; M T LAFORET; F H GARDNER
Journal:  Blood       Date:  1961-01       Impact factor: 22.113

4.  The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena.

Authors:  L PILLEMER; L BLUM; I H LEPOW; O A ROSS; E W TODD; A C WARDLAW
Journal:  Science       Date:  1954-08-20       Impact factor: 47.728

Review 5.  Structure and activation of the early components of complement.

Authors:  R R Porter
Journal:  Fed Proc       Date:  1977-08

6.  Lysis of human cultured lymphoblastoid cells by cell-induced activation of the properdin pathway.

Authors:  A N Theofilopoulos; L H Perrin
Journal:  Science       Date:  1977-03-04       Impact factor: 47.728

7.  Humoral immunostimulation. VII. Sialic acid masks antigenic sites on an antibody-selected bariant cell line.

Authors:  W T Shearer; C Gottlieb; S Kornfeld
Journal:  J Immunol       Date:  1977-08       Impact factor: 5.422

8.  Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution.

Authors:  M K Pangburn; R D Schreiber; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

9.  Modulation of the alternative complement pathways by beta 1 H globulin.

Authors:  K Whaley; S Ruddy
Journal:  J Exp Med       Date:  1976-11-02       Impact factor: 14.307

10.  INTERFERENCE WITH IMMUNE HEMOLYSIS BY GLYCOPROTEIN ANTIGENS.

Authors:  E R ARQUILLA; S HAMASHIGE; J HAMLIN; A MILLER
Journal:  J Exp Med       Date:  1964-11-01       Impact factor: 14.307

View more
  149 in total

1.  Cloning and characterization of gp36, a human mucin-type glycoprotein preferentially expressed in vascular endothelium.

Authors:  G Zimmer; F Oeffner; V Von Messling; T Tschernig; H J Gröness; H D Klenk; G Herrler
Journal:  Biochem J       Date:  1999-07-15       Impact factor: 3.857

2.  Limited tryptic cleavage of complement factor H abrogates recognition of sialic acid-containing surfaces by the alternative pathway of complement.

Authors:  V Koistinen
Journal:  Biochem J       Date:  1992-04-15       Impact factor: 3.857

Review 3.  Target recognition failure by the nonspecific defense system: surface constituents of pathogens interfere with the alternative pathway of complement activation.

Authors:  R D Horstmann
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

Review 4.  Multifarious roles of sialic acids in immunity.

Authors:  Ajit Varki; Pascal Gagneux
Journal:  Ann N Y Acad Sci       Date:  2012-04       Impact factor: 5.691

5.  The relative roles of factor H binding protein, neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci.

Authors:  Lisa A Lewis; Matthew Carter; Sanjay Ram
Journal:  J Immunol       Date:  2012-04-13       Impact factor: 5.422

Review 6.  Complement control protein factor H: the good, the bad, and the inadequate.

Authors:  Viviana P Ferreira; Michael K Pangburn; Claudio Cortés
Journal:  Mol Immunol       Date:  2010-08       Impact factor: 4.407

7.  Identification of complement regulatory domains in vaccinia virus complement control protein.

Authors:  Jayati Mullick; John Bernet; Yogesh Panse; Sharanabasava Hallihosur; Akhilesh K Singh; Arvind Sahu
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

8.  High-density lipoproteins are a potential therapeutic target for age-related macular degeneration.

Authors:  Una L Kelly; Daniel Grigsby; Martha A Cady; Michael Landowski; Nikolai P Skiba; Jian Liu; Alan T Remaley; Mikael Klingeborn; Catherine Bowes Rickman
Journal:  J Biol Chem       Date:  2020-07-31       Impact factor: 5.157

9.  Definition of a bacterial virulence factor: sialylation of the group B streptococcal capsule.

Authors:  M R Wessels; C E Rubens; V J Benedí; D L Kasper
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

10.  Defining targets for complement components C4b and C3b on the pathogenic neisseriae.

Authors:  Lisa A Lewis; Sanjay Ram; Alpana Prasad; Sunita Gulati; Silke Getzlaff; Anna M Blom; Ulrich Vogel; Peter A Rice
Journal:  Infect Immun       Date:  2007-11-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.